-

Abstract

Local endocrine factors (autacoids, paracrine agents), which are secreted from vessel’s endothelium, provide to arrange of vascular tonus. Some of these factors cause vessel relaxation (vasodilator) such as nitric oxide (NO) and prostaglandin-I2 (PGI2); some others cause vessel spasm (vasoconstrictor) such as endothelin (ET)-1 and angiothensin-II. Described in 1988 by Yanagisawa and at al., ET-1 synthesized in vessel endothelium; with its long lasting effect and slow releasing, it is presently one of the strongest vasoconstrictor agents contrary to NO. ET, derived from vessel endothelium is ubiquitous peptide, acts as promitogens and plays an important role during embryonic development. Existence of three distinct genes for ET has been determined which are called ET-1, ET-2, ET-3 and encodes three distinct peptides. However, ET-1 is the isopeptide which is found in greatest concentration in the blood and mainly synthesized by the human endothelium. All three ET isoforms include four cysteine residues, which connect to disulphide bonding (Cys1-Cys15; Cys3-Cys11). ET-1, which has twenty-one amino acids residue, realizes biological effects via cell surface ETA and ETB reseptors, which are 7-transmembrane receptors coupled to G-proteins. ET receptor antagonists submit a new therapeutic area for serious diseases such as congestive heart failure, pulmonary hypertension, arterial hypertension, prostate hypertrophy, prostate cancers, preeclampsia, atherosclerosis and renal failure

Keywords

• Endothelins, endothelin-1, endothelin receptor antagonists, autacoids

Endotelinler: Vazoaktif Peptidler

Öz

Damar endotelyumundan salgılanan lokal hormonal faktörler (otokoidler, parakrin ajanlar) damar tonusunun düzenlenmesini sağlarlar. Bu faktörlerden nitrik oksit (NO), prostaglandin-I2 (PGI2) gibi bir kısmı damar gevşetici (vazodilatatör) olarak düzenleme yapar, endotelin (ET)–1, anjiotensin-II gibi diğer bir kısmı da damar büzücü (vazokonstriktör) olarak işlev görür. Yanagisawa ve ark. tarafından 1988 yılında tanımlanan, damar endotelyumundan sentezlenen ET–1; NO’nun aksine, uzun etki süresi ve yavaş salınımı ile, bilinen en güçlü vazokonstriktör ajanlardan biridir. Damar endotelyumundan kaynaklanan ET insan vücudunda hemen her yerde bulunur, promitojen olarak etki eder ve embriyonik gelişimde önemli bir rol oynar. ET için üç ayrı peptidi kodlayan ve ET–1, ET–2, ET–3 olarak adlandırılan üç farklı genin varlığı saptanmıştır. Ancak kanda en yüksek konsantrasyonda bulunan ve insan endotelyumu tarafından başlıca sentezlenen izopeptid ET-1’dir. Her üç ET isoformu, aralarında disülfit bağının yer aldığı (Cys1 - Cys15; Cys3 -Cys11) dört sistein rezidüsü içerir. Yirmi bir amino asit rezidüsüne sahip ET-1, biyolojik etkilerini G proteinine bağlı zarı 7 defa geçen ETA ve ETB reseptörleri aracılığıyla gerçekleştirir. ET reseptör antagonistleri konjestif kalp yetmezliği, pulmoner hipertansiyon, arteryel hipertansiyon, prostat hipertrofisi, prostat kanserleri, preeklamsi, ateroskleroz ve böbrek yetmezliği gibi ciddi hastalıklar için yeni bir tedavi edici saha sunmaktadır.

Anahtar Kelimeler

• Endotelin, endotelin–1, endotelin reseptör antagonistleri, otakoidler

Kaynakça

1. Goto K. Pulmonary actions of endothelins-history of endothelin. Birkhauser Verlag Basel. Switzerland. 1999;1:1-20
2. Moncada S, Gryglewski R, Bunting S, Vane JR. An from prostaglandin endoperoxides to an unstable substance that 1976;263:663-665 arteries transforms inhibits platelet aggregation. Nature.
3. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376
4. Hickey KA, Rubanyi G, Paul RJ, Highsmith RF. a Characterization produced by cultured endothelial cells. The American journal of physiology. 1985;248:C550-556 coronary vasoconstrictor
5. Masaki T. The discovery of endothelins. . Cardivas Res. 1998;39:530-533
6. Rubanyi GM, Polokoff MA. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994;46:325-415
7. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415
8. Ortega Mateo A, de Artinano AA. Highlights on endothelins: A review. Pharmacological research : the official journal of the Italian Pharmacological Society. 1997;36:339-351

9. Rossi GP, Seccia TM, Albertin G, Pessina AC. Measurement of endothelin: Clinical and research use. Ann Clin Biochem. 2000;37 ( Pt 5):608-626
10. Goto K. Basic and therapeutic relevance of endothelin- mediated regulation. Biol Pharm Bull. 2001;24:1219- 1230
11. D'Orleans-Juste P, Labonte J, Bkaily G, Choufani S, Plante M, Honore JC. Function of the endothelin(b) receptor in pathophysiology. Pharmacol Ther. 2002;95:221-238
12. Benigni A, Remuzzi G. Endothelin antagonists. Lancet. physiology and 1999;353:133-138
13. Warren R, Liu G. Zd4054: A specific endothelin a with metastatic castration-resistant prostate cancer. Expert opinion on investigational drugs. 2008;17:1237-1245 promising activity in the biochemistry, and behavior. 1999;64:171-176 administration rats. Pharmacology, in conscious
14. Bouallegue A, Daou GB, Srivastava AK. Endothelin-1- induced signaling pathways in vascular smooth muscle cells. Current vascular pharmacology. 2007;5:45-52
15. Zhang YM, Wang KQ, Zhou GM, Zuo J, Ge JB. Endothelin-1 promoted proliferation of vascular smooth muscle cell through pathway of extracellular signal- regulated kinase and cyclin d1. Acta Pharmacol Sin. 2003;24:563-568
16. Maeda S, Tanabe T, Miyauchi T, Otsuki T, Sugawara J, Iemitsu M, Kuno S, Ajisaka R, Yamaguchi I, Matsuda M. Aerobic exercise training reduces plasma endothelin-1 concentration in older women. J Appl Physiol. 2003;95:336-341
17. Morganti A, Marana I, Airoldi F, Alberti C, Nador B, Palatresi S. Plasma endothelin levels: A meaningless number? J Cardiovasc Pharmacol. 2000;35:S21-23
18. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin-1 by etb receptors in rats. Biochem Biophys Res Commun. 1994;199:1461-1465
19. Eberl LP, Egidy G, Pinet F, Juillerat-Jeanneret L. Endothelin receptor blockade potentiates fasl-induced apoptosis in colon carcinoma cells via the protein kinase 2000;36:S354-356 Cardiovasc Pharmacol.
20. Gulati A, Srimal, R.C. . Endothelin mechanisms in the central nervous system: A target for drug development. Drug Dev Res 2004;26:361-387
21. Ray A, Hegde LG, Chugh A, Gupta JB. Endothelin- receptor antagonists: Current and future perspectives. Drug discovery today. 2000;5:455-464
22. Growcott JW. Preclinical anticancer activity of the specific endothelin a receptor antagonist zd4054. Anticancer Drugs. 2009;20:83-88
23. Wu C. Recent discovery and development of endothelin receptor antagonists. Exp Opin Ther Patents. 2000;10:1653-1668
24. Ohkita M, Takaoka M, Matsumura Y. Drug discovery for overcoming chronic kidney disease (ckd): The endothelin et b receptor/nitric oxide system functions as a protective factor in ckd. J Pharmacol Sci. 2009;109:7-13
25. Lahav R, Heffner G, Patterson PH. An endothelin receptor b antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci U S A. 1999;96:11496-11500
26. Koyama Y, Takemura M, Fujiki K, Ishikawa N, Shigenaga Y, Baba A. Bq788, an endothelin et(b) receptor antagonist, attenuates stab wound injury- induced reactive astrocytes in rat brain. Glia. 1999;26:268-271
27. Hunley TE, Kon V. Update on endothelins - biology implications. and 2001;16:752-762 Pediatr Nephrol.
28. Schiffrin EL. Endothelin: Potential role in hypertension and 1995;25:1135-1143 Hypertension.
29. Xu CB, Sun Y, Edvinsson L. Cardiovascular risk factors regulate the expression of vascular endothelin receptors. Pharmacol Ther. 2010;127:148-155
30. Kalani M. The importance of endothelin-1 for microvascular dysfunction in diabetes. Vasc Health Risk Manag. 2008;4:1061-1068
31. Adamiec-Mroczek J, Oficjalska-Mlynczak J, Misiuk- Hojlo M. Roles of endothelin-1 and selected proinflammatory cytokines in the pathogenesis of proliferative diabetic retinopathy: Analysis of vitreous samples. Cytokine. 2010;49:269-274
32. Rodeheffer RJ, Lerman A, Heublein DM, Burnett JC, Jr. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc. 1992;67:719-724
33. Schumacher WA, Steinbacher TE, Allen GT, Ogletree ML. Role of thromboxane receptor activation in the bronchospastic Prostaglandins. 1990;40:71-79 to endothelin.
34. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739
35. Ohkita M, Tawa M, Kitada K, Matsumura Y. Pathophysiological roles of endothelin receptors in cardiovascular diseases. Journal of pharmacological sciences. 2012;119:302-313
36. Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor hypertension. 2013;2:CD004434 pulmonary arterial Rev. Cochrane Database Syst
37. Kaasjager KA, Shaw S, Koomans HA, Rabelink TJ. Role of endothelin receptor subtypes in the systemic and renal responses to endothelin-1 in humans. J Am Soc Nephrol. 1997;8:32-39
38. Takahashi K, Totsune K, Mouri T. Endothelin in chronic renal failure. Nephron. 1994;66:373-379
39. Macrae IM, Robinson MJ, Graham DI, Reid JL, McCulloch J. Endothelin-1-induced reductions in cerebral blood flow: Dose dependency, time course, and neuropathological consequences. J Cereb Blood Flow Metab. 1993;13:276-284
40. Swigris JJ, Brown KK. The role of endothelin-1 in the idiopathic pathogenesis BioDrugs. 2010;24:49-54 pulmonary fibrosis.
41. Uguccioni M, Pulsatelli L, Grigolo B, Facchini A, Fasano L, Cinti C, Fabbri M, Gasbarrini G, Meliconi R. Endothelin-1 in idiopathic pulmonary fibrosis. J Clin Pathol. 1995;48:330-334
42. Schroll S, Arzt M, Sebah D, Nuchterlein M, Blumberg F, Pfeifer M. Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist bosentan. Respir Physiol Neurobiol. 2010;170:32-36
43. Knoll T, Schult S, Birck R, Braun C, Michel MS, Bross S, Juenemann KP, Kirchengast M, Rohmeiss P. Therapeutic administration of an endothelin-a receptor antagonist after acute ischemic renal failure dose- dependently improves recovery of renal function. J Cardiovasc Pharmacol. 2001;37:483-488
44. Ahlborg G, Lundberg JM. Nitric oxide-endothelin-1 interaction in humans. J Appl Physiol. 1997;82:1593- 1600
45. Gourine AV, Gonon AT, Pernow J. Involvement of nitric oxide in cardioprotective effect of endothelin receptor antagonist during ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2001;280:H1105-1112
46. Gonon AT, Gourine AV, Pernow J. Cardioprotection from ischemia and reperfusion injury by an endothelin a-receptor antagonist in relation to nitric oxide production. J Cardiovasc Pharmacol. 2000;36:405-412
47. Erdogan H, Fadillioglu E, Emre MH. Protection from renal ischemia reperfusion injury by an endothelin-a receptor antagonist bq-123 in relation to nitric oxide production. Toxicology. 2006;228:219-228
48. Emre MH, Erdogan H, Fadillioglu E. Effect of bq-123 and nitric oxide inhibition on liver in rats after renal ischemia-reperfusion injury. Gen Physiol Biophys. 2006;25:195-206